EUR 107.58 For Business Accounts Only

Epizyme Inc (EPZM) - Strategic SWOT Analysis Review

Epizyme Inc (EPZM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. Its lead product candidate tazemetostat is a first-in-class EZH2 inhibitor finds application in hematological malignancies and solid tumors as a monotherapy and combination therapy in relapsed or refractory non-Hodgkin lymphoma. The company’s other pipeline products include EZM8266 for sickle cell disease; protein arginine methyltransferase (PRMT) inhibitors for solid tumors, B- cell lymphoma and blood cancer; Pinometostat for acute leukemia. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

Aug 09,2019: Epizyme reports business progress and second quarter 2019 results
Jul 22,2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer
May 06,2019: Epizyme provides business update and reports first quarter 2019 financial results
Feb 26,2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results
Nov 19,2018: Boehringer partners with Epizyme to develop new cancer therapies

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.